I. Product Features

1. Broad-spectrum:

Selected from high-quality strains with broad coverage and comprehensive cross-protection. The Newcastle disease virus strain A-VII is a genetically engineered attenuated strain of type VII developed through 17 years of research by Academician Liu Xiufan and his team at the Chinese Academy of Engineering using reverse genetics technology. It exhibits strong immunogenicity and complete compatibility with currently circulating strains, providing effective immune protection while also reducing viral transmission.

After immunized chickens were inoculated, the viral load and excretion levels in the A-VII strain group decreased by 10 to 100 times compared to those in the La Sota strain group.

The H9 subtype avian influenza virus strain WJ57 was selected from the currently dominant circulating strains in China and incorporates advantages of other prevalent strains, exhibiting excellent immunogenicity and cross-protection.

2. Efficient:

It exhibits high antigen content, excellent immunogenicity, rapid antibody production post-immmunization, and high antibody titers.

The antibody levels rise rapidly after immunization, with a peak occurring 7 days earlier than that of La Sota antibodies.

Immunological efficacy of AA+ broiler chicks and protection test against ND virus infection

Results: As shown in the table, low doses of the vaccine can induce high levels of antibodies and demonstrate superior resistance to highly virulent infections compared to other Newcastle disease vaccines.

Immunoprophylactic efficacy study of H9 subtype avian influenza isolates in different regions

Results: As shown in the table, no viral shedding was detected on day 7 post-inoculation, indicating that Nannong Hi-Tech Xinliu qing exhibits strong cross-protection against H9 subtype avian influenza strains isolated from different regions and can inhibit viral shedding.

3. Refining:

This vaccine employs high-quality imported adjuvants to ensure consistent quality. Based on internationally recognized premium medical white oil, it is specifically formulated according to carbon number distribution criteria. The vaccine exhibits low viscosity and minimal immune adverse reactions, facilitating injection and absorption. It achieves sustained antigen release, continuously stimulates the immune system, promotes faster and higher antibody production, and maintains prolonged efficacy.

4. Pure:

Antigen purification was performed using a continuous centrifugation process to remove urate salts and abundant impurity proteins, thereby reducing adverse reactions.

5. Safety:

Strict quality control measures are implemented, including monitoring of vaccine emulsification efficacy, viscosity testing, and endotoxin control in semi-finished antigens. The production process adopts the "High-Tech Unique" methodology employed by internationally leading vaccine manufacturers, ensuring vaccine homogeneity, stability, purity, and enhanced safety during use.

II. Product Usage

[Active Ingredients]The vaccine contains inactivated recombinant Newcastle disease virus strain A-VII and inactivated avian influenza virus (H9 subtype) strain WJ57.

[Properties] A uniform, milky white emulsion.

[Action and Application] Used for the prevention of Newcastle disease in chickens and H9 subtype avian influenza. Immunity is developed 21 days after vaccination.

[Dosage and Administration] Administer subcutaneously or intramuscularly in the neck. For chicks under 3 weeks of age, administer 0.2 mL per bird; the immunization period is 4 months. For chicks aged 3 weeks and above, administer 0.5 mL per bird; the immunization period is 6 months.

[Adverse reactions] Generally, no observable adverse reactions were observed.

[matters need attention]

(1) This product shall be used for immunization of healthy chickens under veterinary supervision.

(2) The vaccine must be carefully inspected prior to use. It shall not be employed if any of the following abnormalities are observed: discoloration, emulsion breakdown, leakage, or presence of foreign particles.

(3) Before use, the vaccine should be restored to room temperature and thoroughly shaken.

(4) Vaccination equipment must be sterile, and the injection site must be disinfected.

(5) The vaccine shall be used only on the day it is dispensed.

(6) Used vaccine vials, equipment, and unused vaccines shall be disposed of through harmless treatment.

(7) Vaccines must not be frozen or stored at high temperatures during transportation and storage.

(8) Prohibited use within 28 days prior to slaughter.

[Packaging Specifications] 500 ml/bottle × 20 bottles/box; 250 ml/bottle × 40 bottles/box.

[Storage and Shelf Life] 2–8°C; shelf life: 18 months